Results 41 to 50 of about 152,878 (197)

A case of food and aeroallergen sublingual immunotherapy inducing eosinophilic esophagitis

Journal of Allergy and Clinical Immunology: Global, 2023
Eosinophilic esophagitis (EoE) has been reported secondary to aeroallergen sublingual immunotherapy (SLIT) and food allergen oral immunotherapy. Gastrointestinal symptoms with food allergen SLIT are uncommon, with no prior reports of cases of food ...
Maureen Bauer, MD, Dan Atkins, MD, Nathalie Nguyen, MD   +2 more
doaj   +1 more source

Efficacy and Safety of Intralymphatic Immunotherapy With Grass Allergoid and Microcrystalline Tyrosine: A Double‐Blind Randomised Placebo‐Controlled Trial

Allergy, EarlyView.
This is the first randomised placebo‐controlled trial of intralymphatic immunotherapy using a microcrystalline tyrosine‐adjuvanted grass pollen allergoid. Three ultrasound‐guided ILIT injections were well tolerated and reduced combined symptom‐medication scores compared with placebo. The findings support further optimisation and clinical development of
Lara Šošić, Stephan C. Flory, Claudia C. V. Lang, Emma C. Widmer, Alexandra Chabot, Johannes M. Schmid, Tobias Andermatt, David Melillo, Bjarke Hviid‐Vyff, Maibritt Mardahl, Peter Schmid‐Grendelmeier, Thomas M. Kündig, Hans Jürgen Hoffmann, Pål Johansen   +13 more
wiley   +1 more source

Is Sublingual Immunotherapy the Final Answer? Implications for the Allergist

World Allergy Organization Journal, 2008
Sublingual immunotherapy (SLIT) is now accepted as a viable alternative to the traditional injection route based on more than 40 clinical trials and several meta-analyses of efficacy.
Giorgio Walter Canonica, MD, Giovanni Passalacqua, MD   +1 more
doaj   +1 more source

Developmental history of sublingual immunotherapy

Folia Pharmacologica Japonica, 2019
Allergen immunotherapy is the only curative treatment for IgE-mediated allergic diseases in contrast to symptomatic treatment such as anti-histamine agents. Subcutaneous immunotherapy (SCIT) has been introduced in Japan for treatment of allergic rhinitis and/or asthma caused by pollens and/or house dust mites (HDM) in early 1960s, and the clinical ...
Weibin, Du, Yuriko, Maekawa, Kensuke, Natsui   +2 more
openaire   +4 more sources

Factors for Success and Failure of Allergen Immunotherapy (AIT) Trial Design in the Light of Evidence‐Based Medicine: Current Aspects 2026

Allergy, EarlyView.
ABSTRACT Allergen immunotherapy (AIT) has been acknowledged as the only disease‐modifying treatment for respiratory diseases since its introduction in 1911. Although the efficacy and safety have convincingly been established in numerous randomized clinical trials (RCTs), the AIT study results may vary substantially.
Roy Gerth van Wijk, Vera Mahler, Melanie Albrecht, Danilo di Bona, Benjamin Hofner, Jasper Kappen, Susanne Kaul, Graham Roberts, Mohamed H. Shamji, Stefan Vieths, Oliver Pfaar   +10 more
wiley   +1 more source

Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy

Allergy, EarlyView.
We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,
Musa R. Khaitov, Maria G. Byazrova, Evgenii V. Smolnikov, Vladislav N. Turenko, Valeriy V. Smirnov, Igor P. Shilovskii, Nadezhda N. Shershakova, Ekaterina N. Medunitsyna, Olga G. Elisyutina, Mikhail V. Pashenkov, George B. Pasikhov, Vladimir V. Murugin, Veronika A. Parshina, Darya K. Bolyakina, Anastasia S. Primak, Mariya A. Lapyko, Inna V. Danilycheva, Rosalia V. Schubelko, Anastasia A. Tsyvkina, Nataliia V. Shartanova, Daria O. Timoshenko, Irina I. Isakova, Tatiana V. Latysheva, Andrey E. Shulzhenko, Elena A. Latysheva, Oksana M. Kurbacheva, Elena S. Fedenko, Oksana A. Markova, Ilya A. Korotkevich, Violetta V. Yan, Natalia A. Gavrilova, Mariia V. Tikhomirova, Ivan V. Shevchenko, Alena A. Agafonova, Gregory N. Poroshin, Dmitry A. Kudlay, Alexander V. Filatov, Evgeniya V. Nazarova, Daria S. Kruchko, Dmitriy V. Goryachev, Vadim A. Merkulov, Nataliya I. Ilina, Rudolf Valenta, Veronica I. Skvortsova   +43 more
wiley   +1 more source

Local side effects during sublingual allergen-specific immunotherapy and pathogenetically based methods for their correction (Review)

Аллергология и Иммунология в Педиатрии
Introduction. The study of the effectiveness and safety of allergen-specific immunotherapy remains relevant due to the emergence of a personalized approach in allergology and new dosage forms.
V. Ya. Zakurskaya
doaj   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Sublingual immunotherapy for allergy to shrimp: the nine-year clinical experience of a Midwest Allergy-Immunology practice

Allergy, Asthma & Clinical Immunology
Background Diet restrictions and fear of adverse reactions put a significant burden on the nutrition, growth and life style of children and adults with food allergies.
Lydia M. Theodoropoulou, Niamh A. Cullen
doaj   +1 more source

Current status of sublingual immunotherapy for allergic rhinitis in Japan

Allergology International, 2018
Japanese cedar pollen (JCP) and house dust mite (HDM) are two major allergens that cause allergic rhinitis (AR) in Japan and the prevalence of AR is increasing.
Keisuke Masuyama, Tomokazu Matsuoka, Atsushi Kamijo   +2 more
doaj   +1 more source